Related Experiment Video
Updated: Jun 13, 2025

12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
18.8K
Mealtime prediction using wearable insulin pump data to support diabetes management
Baiying Lu1, Yanjun Cui1, Prajakta Belsare2
1Department of Computer Science, Dartmouth College, Hanover, 03755, USA.
Scientific Reports
|September 9, 2024
Summary
Patients with type 1 diabetes often have irregular mealtimes, leading to high blood glucose. This study developed personalized models to predict mealtimes, improving timely insulin dosing and reducing glucose spikes.
Area of Science:
- Biomedical Engineering
- Endocrinology
- Data Science
Background:
- Post-meal hyperglycemia is a common challenge for individuals with diabetes, often resulting from delayed or missed insulin administrations.
- Inconsistent meal timing significantly complicates blood glucose management in type 1 diabetes.
Purpose of the Study:
- To analyze mealtime patterns in type 1 diabetes patients using data from wearable insulin pumps.
- To create personalized predictive models for mealtimes to facilitate timely insulin dosing.
Main Methods:
- Utilized two independent datasets comprising over 45,000 meal logs from 82 type 1 diabetes patients.
- Developed and evaluated personalized Long Short-Term Memory (LSTM)-based models for mealtime prediction.
Main Results:
- Identified that over 60% of patients exhibit irregular and inconsistent mealtime patterns.
- Demonstrated the feasibility of predicting future mealtimes with personalized LSTM models, achieving over 95% F1 score and fewer than 0.25 false positives daily.
- Observed significant daily and monthly variations in individual meal timing.
Conclusions:
- Personalized predictive models show high accuracy in forecasting mealtimes for individuals with type 1 diabetes.
- This research provides a foundation for a meal prediction system to aid in timely insulin bolus delivery.
- Reducing post-meal glucose spikes through proactive insulin administration is a key potential benefit.
Related Concept Videos
Insulin: Dosing Regimen and Adverse Effects
157
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
157
Insulin Formulations: Types and Delivery
177
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
177
Diabetes: Management and Pharmacotherapy
245
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
245
Hypoglycemia and Glucagon
216
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
216

